The Effect of Carvedilol on Morbidity and Mortality in Patients with Chronic Heart Failure

Abstract

Carvedilol reduces the risk or death as well as the risk of hospitalization for cardiovascular causes in patients with heart failure who are receiving treatment with digoxin, diuretics, and an angiotensin-converting-enzyme inhibitor.

Keywords

MedicineCarvedilolHeart failureCardiologyInternal medicineIntensive care medicine

MeSH Terms

Adrenergic alpha-AntagonistsAdrenergic beta-AntagonistsCarbazolesCardiovascular DiseasesCarvedilolChronic DiseaseDisease-Free SurvivalDouble-Blind MethodFemaleFree Radical ScavengersHeart FailureHospitalizationHumansMaleMiddle AgedPropanolaminesRisk

Affiliated Institutions

Related Publications

Prediction of Mortality and Morbidity With a 6-Minute Walk Test in Patients With Left Ventricular Dysfunction

Vera Bittner

<h3>Objective.</h3> —To study the potential usefulness of the 6-minute walk test, a self-paced submaximal exercise test, as a prognostic indicator in patients with left ventricu...

1993 JAMA 691 citations

Captopril Treatment of Chronic Heart Failure in the Very Old

Veerle De Bock , Tony Mets , Marco Romagnoli +1 more

The study gives further evidence that angiotensin-converting enzyme inhibitor treatment for very old patients with chronic heart failure is useful.

1994 Journal of Gerontology 24 citations

Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure

Milton Packer , Stefan D. Anker , Javed Butler +36 more

Among patients receiving recommended therapy for heart failure, those in the empagliflozin group had a lower risk of cardiovascular death or hospitalization for heart failure th...

2020 New England Journal of Medicine 4558 citations

Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction

John J.V. McMurray , Scott D. Solomon , Silvio E. Inzucchi +35 more

BACKGROUND In patients with type 2 diabetes, inhibitors of sodium-glucose cotransporter 2 (SGLT2) reduce the risk of a first hospitalization for heart failure, possibly through ...

2019 New England Journal of Medicine 6238 citations

Effects of an Angiotensin-Converting–Enzyme Inhibitor, Ramipril, on Cardiovascular Events in High-Risk Patients

Salim Yusuf , Peter Sleight , Janice Pogue +3 more

Ramipril significantly reduces the rates of death, myocardial infarction, and stroke in a broad range of high-risk patients who are not known to have a low ejection fraction or ...

2000 New England Journal of Medicine 8597 citations

Publication Info

Year: 1996
Type: article
Volume: 334
Issue: 21
Pages: 1349-1355
Citations: 4641
Access: Closed

External Links

Download PDF (Free) View on DOI.org PubMed Semantic Scholar

Social Impact

Altmetric

The Effect of Carvedilol on Morbidity and Mortality in Patients with Chronic Heart Failure

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

4641

OpenAlex

Influential

3667

CrossRef

Cite This

APA Style

                            
                                
                                    Milton Packer, 
                                
                                    Michael R. Bristow, 
                                
                                    Jay N. Cohn
                                
                                et al.
                            
                            (1996). 
                            The Effect of Carvedilol on Morbidity and Mortality in Patients with Chronic Heart Failure. 
                            New England Journal of Medicine
                            , 334
                            (21)
                            , 1349-1355.
                            https://doi.org/10.1056/nejm199605233342101
                        

Identifiers

DOI: 10.1056/nejm199605233342101
PMID: 8614419

Data Quality

Data completeness: 86%